Frasers asks Takeovers Panel to intervene in Accent Group bid
Frasers Group applies to Australia's Takeovers Panel following the rejection of its $390M takeover bid for Accent Group (ASX:AX1).

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Frasers Group applies to Australia's Takeovers Panel following the rejection of its $390M takeover bid for Accent Group (ASX:AX1).
Visa Onchain Analytics reported that Base processed about US$565 billion in adjusted stablecoin transaction volume during June, narrowly exceeding Ethereum (CRYPTO:ETH) at approximately US$562 billion.
Tether invested US$20 million in Mercado Bitcoin to support the Brazilian cryptocurrency platform's expansion into tokenised assets, stablecoin payments, lending and blockchain-based financial services across Latin America.
Nexus Minerals (ASX:NXM) acquired the remaining 10% interest in the Pinnacles Joint Venture Project to reach 100% ownership.
Kenya's Capital Markets Authority announced plans to procure a blockchain analytics platform to monitor cryptocurrency transactions across Bitcoin (CRYPTO:BTC), Ethereum (CRYPTO:ETH) and at least 20 other blockchain networks under the country's new digital asset law.
Telstra (ASX:TLS) experienced a nationwide mobile network outage from approximately 3:00 am on July 8.
Vera Therapeutics (NASDAQ:VERA) received United States FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
Walmart (NASDAQ:WMT) announced extensive price rollbacks on seasonal food items, including ground beef, sodas, and fresh produce to help consumers combat persistent grocery inflation pressures.
Garmin (NYSE:GRMN) introduced its LiveScope 2 Series, a next-generation live-scanning sonar system designed for anglers with updated transducer technology and improved imaging performance.
Vivani Medical (NASDAQ:VANI) signed a new agreement with Novo Nordisk (NYSE:NVO) for a non-exclusive internal evaluation of NPM-139, its semaglutide implant for chronic weight management.